NL1006681C2 - Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. - Google Patents

Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. Download PDF

Info

Publication number
NL1006681C2
NL1006681C2 NL1006681A NL1006681A NL1006681C2 NL 1006681 C2 NL1006681 C2 NL 1006681C2 NL 1006681 A NL1006681 A NL 1006681A NL 1006681 A NL1006681 A NL 1006681A NL 1006681 C2 NL1006681 C2 NL 1006681C2
Authority
NL
Netherlands
Prior art keywords
tissue
use according
damage
vanadium
traumatic event
Prior art date
Application number
NL1006681A
Other languages
English (en)
Dutch (nl)
Inventor
Conradus Ghosal Gho
Original Assignee
Gho St Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL1006681A priority Critical patent/NL1006681C2/nl
Application filed by Gho St Holding Bv filed Critical Gho St Holding Bv
Priority to AU86505/98A priority patent/AU738701B2/en
Priority to CN98809293A priority patent/CN1104244C/zh
Priority to PT98937862T priority patent/PT1001792E/pt
Priority to DK98937862T priority patent/DK1001792T3/da
Priority to DE69819514T priority patent/DE69819514T2/de
Priority to NZ502613A priority patent/NZ502613A/en
Priority to AT98937862T priority patent/ATE253373T1/de
Priority to PL98338415A priority patent/PL338415A1/xx
Priority to ES98937862T priority patent/ES2207851T3/es
Priority to CA002298645A priority patent/CA2298645C/en
Priority to CZ20000326A priority patent/CZ299716B6/cs
Priority to EP98937862A priority patent/EP1001792B1/en
Priority to JP2000504869A priority patent/JP2001511454A/ja
Priority to TR2000/00349T priority patent/TR200000349T2/xx
Priority to IDW20000183A priority patent/ID24870A/id
Priority to BR9811298-8A priority patent/BR9811298A/pt
Priority to EA200000176A priority patent/EA002574B1/ru
Priority to US09/463,697 priority patent/US6579540B1/en
Priority to PCT/NL1998/000431 priority patent/WO1999006056A1/en
Priority to IL13425998A priority patent/IL134259A0/xx
Application granted granted Critical
Publication of NL1006681C2 publication Critical patent/NL1006681C2/nl
Priority to IL134259A priority patent/IL134259A/en
Priority to NO20000446A priority patent/NO20000446L/no
Priority to US10/419,914 priority patent/US20030211170A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NL1006681A 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen. NL1006681C2 (nl)

Priority Applications (24)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
TR2000/00349T TR200000349T2 (tr) 1997-07-29 1998-07-29 Fizyolojik olarak kabul edilebilir vanadyum bileşimlerinin, tuzlarının ve komplekslerinin kullanımı.
JP2000504869A JP2001511454A (ja) 1997-07-29 1998-07-29 生理学的に受容可能なバナジウム化合物，塩および複合体
DK98937862T DK1001792T3 (da) 1997-07-29 1998-07-29 Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
CN98809293A CN1104244C (zh) 1997-07-29 1998-07-29 生理学上可接受的钒化合物、盐和配合物的应用
NZ502613A NZ502613A (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds for the prophylactic treatment of secondary injury of tissue
AT98937862T ATE253373T1 (de) 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
IDW20000183A ID24870A (id) 1997-07-29 1998-07-29 Penggunaan senyawa vanadium, garam dan kompleksnya yang dapat diterima secara fisiologi
ES98937862T ES2207851T3 (es) 1997-07-29 1998-07-29 Uso de compuestos, sales o complejos de vanadio fisiologicamente aceptables.
CA002298645A CA2298645C (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
AU86505/98A AU738701B2 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
EP98937862A EP1001792B1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
PT98937862T PT1001792E (pt) 1997-07-29 1998-07-29 Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
DE69819514T DE69819514T2 (de) 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
PL98338415A PL338415A1 (en) 1997-07-29 1998-07-29 Application of physiologically compatible vanadium compounds, salts and complexes
BR9811298-8A BR9811298A (pt) 1997-07-29 1998-07-29 Uso de um composto de vanádio fisiologicamente aceitável
EA200000176A EA002574B1 (ru) 1997-07-29 1998-07-29 Применение физиологически приемлемых соединений, солей и комплексов ванадия
US09/463,697 US6579540B1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
PCT/NL1998/000431 WO1999006056A1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
IL13425998A IL134259A0 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes
CZ20000326A CZ299716B6 (cs) 1997-07-29 1998-07-29 Použití fyziologicky prijatelné vanadové slouceniny
IL134259A IL134259A (en) 1997-07-29 2000-01-27 Use of physiologically acceptable vanadium compounds, salts and complexes in the preparation of pharmaceutical compositions
NO20000446A NO20000446L (no) 1997-07-29 2000-01-28 Anvendelse av fysiologisk akseptable vanadiumforbindelser, - salter og -komplekser
US10/419,914 US20030211170A1 (en) 1997-07-29 2003-04-21 Use of physiologically acceptable vanadium compounds, salts and complexes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
NL1006681 1997-07-29

Publications (1)

Publication Number Publication Date
NL1006681C2 true NL1006681C2 (nl) 1999-02-08

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Country Status (22)

Country Link
US (2) US6579540B1 (no)
EP (1) EP1001792B1 (no)
JP (1) JP2001511454A (no)
CN (1) CN1104244C (no)
AT (1) ATE253373T1 (no)
AU (1) AU738701B2 (no)
BR (1) BR9811298A (no)
CA (1) CA2298645C (no)
CZ (1) CZ299716B6 (no)
DE (1) DE69819514T2 (no)
DK (1) DK1001792T3 (no)
EA (1) EA002574B1 (no)
ES (1) ES2207851T3 (no)
ID (1) ID24870A (no)
IL (2) IL134259A0 (no)
NL (1) NL1006681C2 (no)
NO (1) NO20000446L (no)
NZ (1) NZ502613A (no)
PL (1) PL338415A1 (no)
PT (1) PT1001792E (no)
TR (1) TR200000349T2 (no)
WO (1) WO1999006056A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
AU1898700A (en) * 1999-12-20 2001-07-03 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and NA+/H+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
AU2008209677B2 (en) 2007-01-31 2013-05-23 Basf Plant Science Gmbh Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same
DE112008001044T5 (de) 2007-05-03 2010-09-02 Basf Plant Science Gmbh Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung
AR067633A1 (es) 2007-07-20 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para producirlas
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
US20110179526A1 (en) 2007-10-29 2011-07-21 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
WO2009135810A1 (en) 2008-05-05 2009-11-12 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
EP2523672B1 (en) 2010-01-15 2016-07-13 Rutgers, the State University of New Jersey Use of vanadium compounds to accelerate bone healing
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
WO2013006798A1 (en) * 2011-07-06 2013-01-10 University Of Medicine And Dentistry Of New Jersey Vandium compounds as therapeutic adjuncts for cartilage regeneration and repair
KR20140048076A (ko) 2010-12-10 2014-04-23 유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 인슐린 모사 제제 복합재로 코팅된 생체 매립가능한 장치 및 이의 방법
PL2683374T3 (pl) * 2011-03-07 2020-04-30 Cfm Pharma Holding Bv Zastosowanie związków wanadu do utrzymania normoglikemii u ssaków
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012563A1 (en) * 1989-04-24 1990-11-01 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
WO1996023811A1 (fr) * 1995-01-31 1996-08-08 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012563A1 (en) * 1989-04-24 1990-11-01 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
WO1996023811A1 (fr) * 1995-01-31 1996-08-08 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ODEKON L E ET AL: "UROKINASE-TYPE PLASMINOGEN ACTIVATOR MEDIATES BASIC FIBROBLAST GROWTH FACTOR-INDUCED BOVINE ENDOTHELIAL CELL MIGRATION INDEPENDENT OF ITS PROTEOLYTIC ACTIVITY", J CELL PHYSIOL, 150 (2). 1992. 258-263., XP002059979 *

Also Published As

Publication number Publication date
DE69819514T2 (de) 2004-09-23
US6579540B1 (en) 2003-06-17
ES2207851T3 (es) 2004-06-01
NO20000446D0 (no) 2000-01-28
EA200000176A1 (ru) 2000-10-30
JP2001511454A (ja) 2001-08-14
TR200000349T2 (tr) 2000-09-21
CA2298645C (en) 2004-05-18
US20030211170A1 (en) 2003-11-13
EP1001792B1 (en) 2003-11-05
DK1001792T3 (da) 2004-01-19
PL338415A1 (en) 2000-11-06
DE69819514D1 (de) 2003-12-11
IL134259A0 (en) 2001-04-30
ATE253373T1 (de) 2003-11-15
ID24870A (id) 2000-08-31
PT1001792E (pt) 2004-03-31
AU8650598A (en) 1999-02-22
CZ2000326A3 (cs) 2000-07-12
IL134259A (en) 2010-02-17
CA2298645A1 (en) 1999-02-11
WO1999006056A1 (en) 1999-02-11
CZ299716B6 (cs) 2008-10-29
NZ502613A (en) 2001-08-31
CN1104244C (zh) 2003-04-02
NO20000446L (no) 2000-03-24
CN1270525A (zh) 2000-10-18
EA002574B1 (ru) 2002-06-27
BR9811298A (pt) 2000-08-29
EP1001792A1 (en) 2000-05-24
AU738701B2 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
NL1006681C2 (nl) Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
Luly et al. Hormonal control in vitro of plasma membrane-bound (Na+− K+)-ATPase of rat liver
EP0655460B1 (de) Pharmazeutisch therapeutische Verwendung von Glutathion-Derivaten
DE69837754T2 (de) Kombinierte tumor suppressor-gen-therapie und chemotherapie bei der neoplasmabehandlung
US20210340541A1 (en) Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
Cameron et al. Total intravenous hyperalimentation and hydroxyurea chemotherapy in hepatoma-bearing rats
NL7909199A (nl) Farmaceutisch preparaat voor het behandelen van nieuw- vormingsziekten en werkwijzen voor het bereiden ervan.
CA2304956C (en) Pharmaceutical composition for preventing or treating ischemic diseases
JPS63501219A (ja) 内分泌系ホルモン生成抑制用非経口投与治療組成物および方法
US20030108620A1 (en) Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a na+/hinhibitors, cyclo-oxygenase inhibitors and caspase inhibitors
NL9300065A (nl) Samenstelling voor het versnellen van wondgenezing.
MXPA00001037A (en) Use of physiologically acceptable vanadium compounds, salts and complexes
JP2002523361A (ja) 白金錯化合物含有医薬並びにその使用
JPH0296535A (ja) 骨髄機能障害性貧血治療剤
NZ519631A (en) Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and at least a component selected from a Na+/H+ exchanger inhibitors, cyclo-oxygenase inhibitors and caspase inhibitors
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
CN115634220B (zh) 二甲双胍在制备预防和/或治疗电磁辐射致生殖损伤的产品中的应用
WO2013003445A1 (en) Tetra-pyridine compounds and composition for protecting cells, tissues and organs against ischemia-reperfusion injury
Shafiroff et al. Subcutaneous administration of combined fat emulsion with hyaluronidase.
KR19980020379A (ko) 사이토킨 성장인자로 인한 질병의 치료방법
RU2146927C1 (ru) Препарат для лечения рака кожи и предраковых заболеваний кожи
CN1688332A (zh) 成骨生长肽对红系造血组细胞的促增殖作用及应用
JPH0272123A (ja) ヒト上皮細胞成長因子の投与方法及びヒト上皮細胞成長因子含有疾病治療剤

Legal Events

Date Code Title Description
PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20050201